Please assess the completion status of the following clinical trial:

Trial Title: Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must have signed an inform consent document~* Have histologic or cytologic diagnosis of breast cancer with evidence of unresectable locally recurrent or metastatic disease~* Have not received any prior chemotherapy for locally recurrent or metastatic disease~* Have not had adjuvant or neoadjuvant taxane therapy within 12 months prior to assignment to study treatment~* Age 18 years or older at time of informed consent~Exclusion Criteria:~* Have any clinical evidence of central nervous system (CNS) metastases~* Have a history of seizure~* Have had a major surgical procedure within 4 weeks prior to assignment to study treatment~* Have had a minor surgical procedure, placement of an access device, or fine needle aspiration within 7 days prior to assignment to study treatment~* Have symptomatic peripheral vascular disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Enzastaurin + Bevacizumab + Paclitaxel (Type: EXPERIMENTAL): Participants randomized to this arm (Arm A) will receive enzastaurin, paclitaxel and bevacizumab until disease progression.~Prior to randomization, a safety lead-in will be conducted in 6 participants who will be treated according to Arm A for 2 cycles (1 cycle = 28 days). Only after an acceptable safety analysis of the safety lead-in, will other participants be randomized to Phase 2 (either Arm A or Arm B). In Phase 2, participants from the safety lead-in will continue treatment according to Enzastaurin + Bevacizumab + Paclitaxel (Arm A).
- Bevacizumab + Paclitaxel + Placebo (Type: PLACEBO_COMPARATOR): Participants randomized to this arm (Arm B) will receive bevacizumab, paclitaxel and placebo until disease progression.

Based on this trial design, predict the completion outcome and termination type (if applicable).